London, UK (PRWEB) August 26, 2015
Market Publishers Ltd is happy to inform that in-demand research reports worked out by GBI Research have been recently uploaded to its catalogue.
Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation. The various oncology indications are the key cause of death in economically developed nations and the second-largest cause of death in developing nations and also present a leading health burden worldwide. Across the overall pharmaceutical industry, the oncology pipeline is much larger compared to any other therapy area. Owing to a degree of crossover between oncology indications regarding their underlying pathophysiology, it is common for products developed for this therapy area to have developmental programmes testing them across manifold indications. The report provides an in-depth understanding of the present-day commercial and clinical landscape in the oncology marketplace; analyses the 20 most common indications; canvasses the oncology market and oncology pipeline; examines the therapeutic potential and developmental footprint of various first-in-class targets and highlights the most promising ones.
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline. Hypertension affected 517 million people as of 2014, a figure that will grow at a CAGR of 1.2% to 561 million by 2021 in China, Australia, India and Japan. This high prevalence is a key contributor to healthcare expenses and a leading cause of morbidity. In spite of this, awareness of hypertension is low amongst physicians, patients, and the public, resulting in the poor control of blood pressure. Through to 2021, the value of the APAC anti-hypertensive therapeutics market is forecast to increase from USD 15.7 billion to just over USD 19.9 billion, registering a CAGR of 3.4%. The growing prevalence of hypertension is driving the market growth in spite of weak pipeline. The study is an indispensible guide to the anti-hypertensive market across the Asia-Pacific to 2021.
Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments. Multiple myeloma (MM) is the 2nd-most frequently diagnosed hematological malignancy, with an annual prevalence in the USA of close to 45,000. The disease is deemed to be incurable, although the past ten years have seen grteat improvements in therapy, fuelled by a more refined understanding of pathophysiology. The MM market landscape has gone through dramatic changes over the past two decades. The sector is forecast to increase from a value of USD 7.3 billion as of 2014 to USD 8.9 billion by 2021, posting just under 3% CAGR across the 8 key markets examined. Many of the leading drugs in the market were approved during the last 10–15 years, having enhanced median overall survival rates by nearly 50%. The MM pipeline comprises 267 drug products in active development, including a set of molecule types and therapeutic targets. The innovation that has characterised the market in the recent past is also distinctly present in today’s pipeline, with a strong presence of new, targeted products. More important information and data on the market can be found in the report.
More reports created by the publisher can be found at GBI Research page.